Literature DB >> 3575019

Influence of transcutaneous oxygen monitoring on the incidence of retinopathy of prematurity.

E Bancalari, J Flynn, R N Goldberg, R Bawol, J Cassady, J Schiffman, W Feuer, J Roberts, D Gillings, E Sim.   

Abstract

This study was performed to determine whether the use of continuous transcutaneous oxygen tension (tcPO2) monitoring could reduce the incidence of retinopathy of prematurity in preterm infants receiving oxygen therapy. A total of 296 infants with birth weights less than or equal to 1,300 g were randomly assigned to a continuous monitoring or a standard care group. Infants in the continuous monitoring group had tcPO2 monitored continuously as long as they required supplemental oxygen, and infants in the standard care group had tcPO2 monitored only during the more acute state of their illness. Management of both groups was otherwise identical. Of 148 infants in the continuous monitoring group, 101 survived; of the 148 patients in the standard care group, 113 survived. Mean birth weights and gestational ages were similar for both groups. Duration of mechanical ventilation and oxygen therapy was also similar. The overall incidence of retinopathy of prematurity was 51% in the continuous monitoring group and 59% in the standard care group. As birth weight for infants greater than or equal to 1,000 g increased, a higher risk of retinopathy of prematurity developing was noted in the standard care group. Cicatricial retinopathy of prematurity developed in four infants in the continuous monitoring group and five in the standard care group. These results suggest that continuous tcPO2 monitoring may reduce the incidence of retinopathy of prematurity in infants with birth weights greater than 1,000 g but not in the smaller infants in whom this complication occurs more frequently and is more severe.

Entities:  

Mesh:

Year:  1987        PMID: 3575019

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  7 in total

1.  An elevated level of copper zinc superoxide dismutase fails to prevent oxygen induced retinopathy in mice.

Authors:  C Klaeger; L de Sa; A J Klaeger; E J Carlson; W V Good; C J Epstein
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

2.  Neonatology--then and now. Oxygen tension in the newborn (1957).

Authors:  C H Walker
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

3.  A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity.

Authors:  J T Flynn; E Bancalari; E S Snyder; R N Goldberg; W Feuer; J Cassady; J Schiffman; H I Feldman; B Bachynski; E Buckley
Journal:  Trans Am Ophthalmol Soc       Date:  1991

4.  Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.

Authors:  Luca Filippi; Giacomo Cavallaro; Patrizio Fiorini; Marta Daniotti; Valentina Benedetti; Gloria Cristofori; Gabriella Araimo; Luca Ramenghi; Agostino La Torre; Pina Fortunato; Liliana Pollazzi; Giancarlo la Marca; Sabrina Malvagia; Paola Bagnoli; Chiara Ristori; Massimo Dal Monte; Anna Rita Bilia; Benedetta Isacchi; Sandra Furlanetto; Francesca Tinelli; Giovanni Cioni; Gianpaolo Donzelli; Silvia Osnaghi; Fabio Mosca
Journal:  BMC Pediatr       Date:  2010-11-18       Impact factor: 2.125

Review 5.  Vascular endothelial growth factor in eye disease.

Authors:  J S Penn; A Madan; R B Caldwell; M Bartoli; R W Caldwell; M E Hartnett
Journal:  Prog Retin Eye Res       Date:  2008-05-28       Impact factor: 21.198

Review 6.  Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants.

Authors:  Lisa M Askie; David J Henderson-Smart; Henry Ko
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 7.  Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again.

Authors:  Mitsuru Arima; Yuya Fujii; Koh-Hei Sonoda
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.